Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics

开发基于 4-(芳酰氨基)哌啶的进入抑制剂作为抗流感疗法

基本信息

  • 批准号:
    10618383
  • 负责人:
  • 金额:
    $ 99.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-02 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

Influenza A viruses belong to the orthomyxoviridae family, and have a negative-sense, segmented RNA genome, which can cause seasonal or pandemic flu with high morbidity and significant mortality. Vaccination is the most prevalent prophylactic means for controlling influenza infections. However, an effective vaccine usually takes at least six months to develop. Furthermore, vaccination has limited effectiveness in the treatment of immunocompromised patients, and its effectiveness is also limited during a pandemic. The current therapeutic options for flu infections are all based on the neuraminidase inhibitors (NAIs; oseltamivir, zanamivir and peramivir), while the influenza M2 ion channel blockers (amantadine and rimantadine) are not now recommended since all of the circulating influenza strains have acquired resistance. (Xofluza, a polymerase acidic endonuclease inhibitor, has just been approved in 2018 and is yet untried during a flu season.) The rapid emergence of the NAI-resistant strains of influenza A viruses strongly suggests that NAIs alone may not be sufficient as effective therapies, and thus new treatment options targeting the other viral/host factors are urgently needed. This application defines a plan to develop potent, small molecule inhibitors, which block entry of influenza A viruses. We have identified compounds that inhibit entry of infectious influenza A viruses, with IC50 values in the nanomolar range. We have synthesized structurally diverse analogs of the anti-influenza hit series using structure-activity relationships (SARs) to improve potency and selectivity; validated the lead inhibitor candidates in the infectious assay and investigated the mechanism of action (MOA) of the these inhibitors; and selected anti-influenza inhibitors with excellent in vitro potency and selectivity values and druglike in vivo pharmacokinetic properties. In this Fast Track STTR Phase I &II application, we propose four specific aims: (1) optimize the lead scaffold and select development candidates; (2) investigate the mechanism of action (MOA) of the advanced lead compounds with HA proteins; (3) evaluate the pharmacokinetics/toxicokinetics of the advanced lead compounds; and (4) preclinical development.
甲型流感病毒属于正粘病毒科,具有负义、分段RNA 基因组,可引起季节性或大流行性流感,发病率高,死亡率高。 接种疫苗是控制流感感染的最普遍的预防手段。但安 有效的疫苗通常需要至少六个月的时间来研制。此外,疫苗接种限制了 在治疗免疫功能低下的患者中,其有效性也有限 在大流行期间。目前流感感染的治疗选择都是基于神经氨酸酶 抑制剂(NAIs;奥司他韦,扎那米韦和帕拉米韦),而流感M2离子通道阻滞剂 (金刚烷胺和金刚乙胺)现在不推荐,因为所有流行的流感病毒株 已经获得了抵抗力。(Xofluza,一种聚合酶酸性核酸内切酶抑制剂, 在2018年,在流感季节尚未尝试。耐NAI菌株的迅速出现, 甲型流感病毒强烈表明,单独的NAI可能不足以作为有效的治疗方法, 因此,迫切需要靶向其它病毒/宿主因子的新的治疗选择。本申请 确定了一项开发有效的小分子抑制剂的计划,该抑制剂可以阻止甲型流感病毒的进入。我们 已经鉴定了抑制传染性甲型流感病毒进入的化合物,其IC 50值在 纳摩尔范围。我们已经合成了抗流感病毒系列的结构多样的类似物, 结构-活性关系(SAR),以提高效力和选择性;验证了先导抑制剂 候选人的感染性试验,并研究了这些的作用机制(MOA) 抑制剂;以及具有优异的体外效力和选择性值的选定的抗流感抑制剂, 类药体内药代动力学特性。在这个快速通道STTR第一和第二阶段的应用,我们建议, 四个具体目标:(1)优化铅支架和选择发展候选人;(2)调查 先进先导化合物与HA蛋白的作用机制(MOA);(3)评估 先进先导化合物的药代动力学/毒理学;和(4)临床前开发。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lijun Rong其他文献

Lijun Rong的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lijun Rong', 18)}}的其他基金

Optimizing Ridaifen-B analogs as potential therapeutics for Ebola viruses
优化 Ridaifen-B 类似物作为埃博拉病毒的潜在疗法
  • 批准号:
    10586633
  • 财政年份:
    2022
  • 资助金额:
    $ 99.94万
  • 项目类别:
Optimizing Ridaifen-B analogs as potential therapeutics for Ebola viruses
优化 Ridaifen-B 类似物作为埃博拉病毒的潜在疗法
  • 批准号:
    10708178
  • 财政年份:
    2022
  • 资助金额:
    $ 99.94万
  • 项目类别:
Furopyrimidines as novel inhibitors of henipaviruses
呋喃嘧啶作为亨尼帕病毒的新型抑制剂
  • 批准号:
    10327725
  • 财政年份:
    2021
  • 资助金额:
    $ 99.94万
  • 项目类别:
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics
开发基于 4-(芳酰氨基)哌啶的进入抑制剂作为抗流感疗法
  • 批准号:
    10256145
  • 财政年份:
    2021
  • 资助金额:
    $ 99.94万
  • 项目类别:
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics
开发基于 4-(芳酰氨基)哌啶的进入抑制剂作为抗流感疗法
  • 批准号:
    10576494
  • 财政年份:
    2021
  • 资助金额:
    $ 99.94万
  • 项目类别:
Development of group 2 influenza A virus entry inhibitors
2 组甲型流感病毒侵入抑制剂的开发
  • 批准号:
    9903216
  • 财政年份:
    2019
  • 资助金额:
    $ 99.94万
  • 项目类别:
4-(Aminomethyl) benzamides as novel anti-Ebola agents
4-(氨甲基)苯甲酰胺作为新型抗埃博拉药物
  • 批准号:
    10207381
  • 财政年份:
    2016
  • 资助金额:
    $ 99.94万
  • 项目类别:
4-Aminopiperidines as novel anti-influenza agents
4-氨基哌啶作为新型抗流感药物
  • 批准号:
    9277398
  • 财政年份:
    2016
  • 资助金额:
    $ 99.94万
  • 项目类别:
GPCR antagonists as anti-Ebola virus entry inhibitors
GPCR 拮抗剂作为抗埃博拉病毒进入抑制剂
  • 批准号:
    8980076
  • 财政年份:
    2015
  • 资助金额:
    $ 99.94万
  • 项目类别:
GPCR antagonists as anti-Ebola virus entry inhibitors
GPCR 拮抗剂作为抗埃博拉病毒进入抑制剂
  • 批准号:
    9090033
  • 财政年份:
    2015
  • 资助金额:
    $ 99.94万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 99.94万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 99.94万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 99.94万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 99.94万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 99.94万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 99.94万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 99.94万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 99.94万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 99.94万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 99.94万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了